LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

Receiving monoclonal antibodies to treat COVID-19 used to be a time-consuming process at the UPMC Hamot Infusion Center. The intravenous treatment took about 30 minutes, which came after a nearly hour ...

While administering monoclonal antibodies via intravenous infusion is standard practice to prevent severe hospitalization and death in outpatients with COVID-19, new research from UPMC shows giving ...

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen ...